MAFB MUTANTS AND USES THEREOF
Publikation: Geistiges Eigentum › Patentanmeldung/Patent
Beitragende
- INSERM - Institut national de la santé et de la recherche médicale
- European Molecular Biology Laboratory (EMBL) Heidelberg
- Centre national de la recherche scientifique (CNRS)
- Aix-Marseille Université
Abstract
The present invention relates to MafB mutants and uses thereof for research, screening and therapeutic purposes. In particular, the present invention relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the glutaminic acid residue at position 269 has been deleted or substituted with a basic amino acid. The present invention also relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the valine residue at position 277 has been deleted or substituted with a polar amino acid.
Details
The present invention relates to MafB mutants and uses thereof for research, screening and therapeutic purposes. In particular, the present invention relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the glutaminic acid residue at position 269 has been deleted or substituted with a basic amino acid. The present invention also relates to a MafB mutant polypeptide comprising the sequence as set forth in SEQ ID NO: 1 or 2 or a function conservative variant thereof wherein the valine residue at position 277 has been deleted or substituted with a polar amino acid.
| Originalsprache | Englisch |
|---|---|
| IPC (Internationale Patentklassifikation) | G01N 33/ 50 A I |
| Veröffentlichungsnummer | US2016304584 |
| Land/Gebiet | Deutschland |
| Prioritätsdatum | 3 Dez. 2014 |
| Prioritätsnummer | WO2014EP76365 |
| Publikationsstatus | Veröffentlicht - 20 Okt. 2016 |